A Dose-exploration Study of EDP167 in HoFH

Exclusion criteria

• . Allergic to the drug in this study, its components or similar drugs.
• . Used any antisense oligonucleotide (ASO) or small interfering nucleic acid (siRNA) drugs within 12 months prior to randomization.
• . Received treatment targeting ANGPTL3 or Apolipoprotein C3 (ApoC3), or have participated in other clinical trials within 6 months or 5 half-life (whichever longer) prior to screening.
• . Received health supplements or other medications that have been used for lipid-lowering purposes within 4 weeks prior to screening.
• . Received Lipoprotein apheresis within 8 weeks prior to screening.
• . A weight change of \>10% within 4 weeks prior to randomization, or planning to undergo weight-loss surgery or weight intervention treatment during the study period.
• . Starting a new diet plan or having significant differences from the previous diet within 4 weeks prior to randomization.
• . Presence of diseases that would affect lipid or lipoprotein levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, hypothyroidism or hyperthyroidism, etc., which are poorly controlled, and in the opinion of the Investigator will interfere with the accurate assessment of the study results.